BELLEVUE, Wash.--(BUSINESS WIRE)--EMulate Therapeutics, Inc. (“Emulate”) announces the Open Journal of Biophysics (OJBIPHY), publisher of over 200 peer-reviewed open access journals, has accepted its manuscript, titled “Magnetic Field Emulations of Small Inhibitor RNA: Effects on Implanted GL261 Tumors in C57BL/6 Immune Competent Mice” for publication. This submission supports independent results in an animal model of Glioblastoma Multiforme (GBM), recently published by Mukthavaram et al. (Bioelectron Med 2024 Vol. 10 Issue 1 Pages 10), which demonstrates the ability of EMulate’s second signal treatment offering, A2. GBM is a rare brain glioma that currently has no established treatment on the market and is categorized by the U.S. Food and Drug Administration (FDA) as a highly underserved orphan disease (affects fewer than 200,000 in the U.S.). https://www.scirp.org/journal/paperinformation?paperid=135320
The paper demonstrates EMulate’s A2 signal treatment targets the established immune checkpoint inhibitor targets of CTLA-4 and PD-1, reducing the expression of these immune system receptors and inhibiting the growth of tumors in a validated mouse model of GBM. These results support the observed outcomes from a Phase I clinical trial (NCT02507102) demonstrating safety and possible efficacy against GBM in humans.
“The results of this pre-clinical animal model study continue to demonstrate the potential of our ulRFE technology in the treatment of cancers and other challenging diseases with high unmet medical needs. We strongly believe in the potential benefits of this treatment in patients afflicted by cancer with these genetic targets, which we intend to confirm in future clinical trials,” stated Xavier Figueroa, Ph.D., EMulate’s SVP of Pre-Clinical Development.
About EMulate Therapeutics, Inc.
EMulate Therapeutics is a clinical stage company utilizing its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to provide safe and effective therapeutic benefits specifically targeted at patients’ underlying conditions. The company has generated encouraging human clinical results from patients afflicted with glioblastoma and diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), and is preparing for pivotal (phase III) studies in each indication using its proprietary A1A treatment signal emulating the mechanism of action of paclitaxel, a well-known and characterized chemotherapy agent. The company has submitted an application to the FDA for approval to treat U.S. patients diagnosed with DMG via the humanitarian device exemption (HDE) regulatory pathway and to commercialize this treatment product. It has also generated encouraging preclinical studies in pain management and mental health models and is preparing for initial human clinical trials in each area. In addition, positive data have been generated independently in animal health (positive cancer results in over 20 different solid tumor types in canines (pets)), as well as in bio-agriculture models. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial stage consumer wellness-wearable technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.
About our ulRFE Device
EMulate Therapeutics (EMTx) has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, portable investigational medical device that uses low to ultra-low level (DC-22kHz) frequencies to create and deliver specific electromagnetic fields that produce specific biological effects, including, e.g., increasing tubulin polymerization in numerous cancer models, emulating the effects of psychedelic drugs in mental health models and reducing pain sensations, among others. The system emits a low power magnetic field (< 100 mG) that can be applied locally or globally, dependent on the type of therapeutic effect sought. The EMTX signals are stored as WAV files on the device and emitted via a cable to the attached antenna unit.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements.” Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “should,” “would,” “plan,” “project,” “forecast,” and “potential,” the negatives thereof or similar expressions. Forward-looking statements speak only as of the date made, are based on various underlying assumptions and current expectations about the future and are not guarantees of future performance. While we believe these assumptions and expectations are reasonable, are made in good faith and have a reasonable basis, assumed facts or bases almost always vary from actual results, and the differences between assumed facts or expectations and actual results can be material, depending on the circumstances. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates, or to regard them as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved.
Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.
